NCT07218627View on ClinicalTrials.gov

A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

January 15, 2027

Conditions

Heart Failure

Interventions

DRUG

NNC0537-1482

NNC0537-1482 will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Trial Locations (1)

SE1 1YR

Richmond Pharmacology, London

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY